NovaBridge Biosciences (NBP) Convertible Debt (2018 - 2020)

NovaBridge Biosciences (NBP) has reported Convertible Debt for 3 consecutive years, with $9.5 million the latest figure, recorded in Q3 2020.

• Quarterly Convertible Debt changed N/A year-over-year to $9.5 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $9.5 million (changed N/A YoY) and the FY2019 annual result came in at $9.8 million, down 3.48% from the prior year.
• Convertible Debt declined to $9.5 million in Q3 2020 per NBP's latest filing, from $9.8 million in the prior quarter.
• Over the last five years, Convertible Debt for NBP reached as high as $9.8 million in Q2 2020 and fell as low as $9.5 million in Q3 2020.
• A 3-year average of $9.7 million and a median of $9.7 million in 2018 frame the typical range for Convertible Debt.
• The largest YoY upside for Convertible Debt was 0.18% in 2019 against a maximum downside of 0.18% in 2019.
• Year by year, Convertible Debt stood at $9.7 million in 2018, then fell by 0.18% to $9.7 million in 2019, then retreated by 1.41% to $9.5 million in 2020.
• According to Business Quant data, Convertible Debt over the past three periods registered $9.5 million, $9.8 million, and $9.7 million for Q3 2020, Q2 2020, and Q4 2019 respectively.